Objective: To evaluate the efficacy and safety of CyberKnife(®) treatment for locally-advanced pancreatic cancer (LAPC).
Methods: The efficacy of CyberKnife(®) treatment was analyzed in 59 LAPC patients treated between October 2006 and September 2014. The median tumor volume was 27.1 mL (13.0-125.145 mL). The median prescribed dose was 45 Gy (35-50 Gy), delivered in 5 fractions (3-8 fractions). The overall survival (OS) rates and freedom from local progression (FFLP) rates were estimated using the Kaplan-Meier survival curve.
Results: The median follow-up for all patients was 10.9 months (3.2-48.7 months) and 15.6 months (3.9-37.6 months) among surviving patients. The median OS was 12.5 months, and the 1-year and 2-year survival rates were 53.9% and 35.1%, respectively. The 1-year FFLP rate was 90.8% based on the computed tomography (CT) evaluation. Grade 1-2 acute and late-stage gastrointestinal (GI) reactions were observed in 61% of the patients. One patient experienced grade 3 toxicity.
Conclusion: Excellent clinical efficacy was obtained after treatment of LAPC using CyberKnife(®), with minimal toxicity.
Keywords: CyberKnife®; local control; pancreatic cancer; stereotactic body radiotherapy; toxicity.